The Cytel Blog: Perspectives on Enquiry & Evidence

There is recognized heterogeneity within any given tumor‐type from patient to patient (inter‐patient heterogeneity),..

Popular statistical designs, such as CRM (O’Quigley et al., 1990), mTPI-2 (Guo et al., 2017), and i3+3 (Liu et al.,..

When selecting clinical trial designs, how many design options should a sponsor explore? Would a sponsor feel more..

For many decades the Pareto Frontier has been employed by actors in the private sector to evaluate and understand the..

Advancements in biomarkers and momentum in precision medicine has paved the foundation for complex studies like basket..

When developing clinical strategy, applying familiar business principles to the specific requirements of clinical..

As healthcare systems across the world, continue to grapple with the pressures of COVID-19, Cytel advances yet another..

Recently, Cytel co-founder Professor Cyrus Mehta noted that, “Clinical trial design selection is too much like an art,..

For much of the past three decades, even as methodologies for clinical trial design have advanced and refined, the idea..